Down 85%! Why Affymax, Inc. (AFFY) is Getting Crushed This Morning

Look out below Affymax, Inc. (NASDAQ:AFFY) investors. The company pulled its only drug off of the market, and shares of the company are indicated to fall around 85% this morning according to Yahoo! Finance.

In collaboration with Japanese pharmaceutical company Takeda, Affymax developed a drug called Omontys for dialysis patients with anemia, or low red blood cell levels. The drug’s benefits over existing treatments had some investors optimistic about its commercial potential. But much of that hope was lost on Saturday morning, when the partners announced a voluntary recall of the drug after a small percentage of patients experienced serious initial side effects, leading to a handful of patient deaths.

Affymax, Inc. (NASDAQ:AFFY)The market Omontys was looking to penetrate is huge, and dominated by industry giants Amgen, Inc. (NASDAQ:AMGN) and Johnson & Johnson (NYSE:JNJ). Amgen’s Epogen and Aranesp combined for more than $2.7 billion in sales in 2012. J&J’s Procrit, which is the same underlying drug as Epogen, brought in nearly $1.5 billion. And while the overall market for the branded anemia drugs has been shrinking, Omontys only has to be taken once a month versus multiple times per week for Procrit and and Epogen. That advantage could have seen the drug take plenty of market share over the long term, despite rising generic competition.

I won’t mince words, this is a crushing blow for Affymax. With its sole drug pulled off of the market for safety concerns, the long term viability of the company is in serious question. But if the company can determine the reasons for the reactions and address them in an acceptable way, this may not be the end for Omontys and Affymax. The adverse events appeared to only happen during the initial dose, which suggests that long term use is safe. However, its clear from premarket activity that investors are expecting the worst.

Management is providing an update to discuss the news at 8:30 a.m. EST. You can access the webcast at Amgen’s investor relations page.

Is bigger really better?
Today’s Affymax news highlights a key consideration for investors when investing in small biotech stocks with highly concentrated risks. However, even the strongest, most diversified health care stocks have their detractors.

The article Down 85%! Why Affymax is Getting Crushed This Morning originally appeared on Fool.com and is written by Brenton Flynn.

Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The 10 Countries with the Highest Suicide Rates

The 10 Most Technologically Advanced Countries in the World

The 10 Safest Countries in the World to Live in Peace

The 10 Top Selling Smartphones in the World 2014

The 12 Biggest Shopping Centers in the World

The 10 Friendliest Countries in the World

Qihoo 360 Technology Co Ltd (QIHU), Actavis plc (ACT), Yahoo! Inc. (YHOO) Among 20 Long Ideas from Sohn Canada

The 10 Laziest Countries in the World

The 10 Most Polluted Countries in the World

The 10 Most Dangerous Cities in America 2014

The Top 10 Gold Producing Countries in the World

The 10 Tallest Buildings in the World

The 10 Richest Stand Up Comedians in the World

The 10 Fattest Countries in the World

The 5 Best Summer Jobs for Teens

The 10 Most Religious Countries in the World Keeping the Faith

The 10 Most Educated Countries in the World

The 10 Most Popular Cell Phones in the World

The 10 Drunkest Countries in the World

The 10 Most Expensive Private Schools in the World

The 10 Smallest Countries in the World

Walking Dead Season 5 Spoilers You’ll Wish You Didn’t Know

The 10 Poorest Countries in the World

The 10 Greenest Countries in the World

The Top 10 Countries with the Highest Population in the World

The 10 Most Visited Countries in the World

The Top 10 Star Wars Characters in the Iconic Series

The 10 Most Expensive Android Phones in the World

5 Reasons Why The Illuminati Is Real and a Threat to Society

The 6 Scariest Halloween Costumes Ever Screamed At

The 4 Biggest Hedge Fund Managers in the World Today

The 15 Most Densely Populated Countries in the World

The 10 Biggest Tea Drinking Countries in the World

Top 6 Ways to Improve Your Checkout Process and Close Sales

The 5 Most Profitable Online Businesses You Can Start Today

The 20 Most Profitable Hospitals in the US

The 5 Most Profitable Home Businesses to Start

The 7 Teams that Will Win the Stanley Cup in 2015

The Top 10 Most Expensive Digital Cameras to Snap Stunning Shots With

The 10 Highest Quality Fast Food Restaurants In America Today

The 8 Best Halloween Decorating Ideas to Spook Up Your House

10 Marvel Women that Should Get a Movie Right Now

The 20 Best Remixes of Popular Songs that Will Make You Forget the Originals

7 Most Expensive Cities in the World

5 Least Expensive Cities in the World

10 Celebrities Who Believe In Scientology

10 High Margin Food Products to Build a Business Around

The 10 Most Expensive Clothing Stores in the United States to Get Decked Out At

The 5 Biggest Kickstarter Scams That Swindled Backers’ Donations

The 10 Most Expensive Boarding Schools In the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!